PRAME peptide 100–108–HLA-A*02:01 peptide–major histocompatibility complex class I complex (PRAME_100–108/HLA-A*02:01 pMHC)

The PRAME_100–108/HLA-A*02:01 peptide–MHC complex is a molecular structure formed when a specific peptide fragment derived from the PRAME (Preferentially Expressed Antigen in Melanoma) protein—residues 100 to 108—is presented on the surface of cells by the major histocompatibility complex class I molecule HLA-A*02:01. This complex is recognized by cytotoxic T lymphocytes and is being pursued as a therapeutic target in cancer immunotherapy, particularly in malignancies where PRAME is overexpressed, such as acute myeloid leukemia and certain solid tumors. Drugs targeting the complex aim to direct T cells or T cell receptor-mimic antibodies to kill cancer cells in an HLA-restricted, antigen-specific manner.

Other names

PRAME_100–108/HLA-A2 complexPRAME/HLA-A*02:01 pMHCPRAME epitope-HLA-A2 complex

T cell receptor mimicry: drugs or antibodies recognize the peptide–MHC complex and trigger T-cell mediated cytotoxicity Adoptive T cell therapy: T cells engineered to express TCRs specific for PRAME_100–108/HLA-A*02:01 recognize and kill tumor cells